SHP099

• Description:

  SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2D61Y, SHP2E69K, SHP2A72V, SHP2E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM) . SHP099 inhibits RAS-ERK signaling and inhibits tumor growth[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H320

• Target:

  Phosphatase; SHP2

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/SHP099.html

• Purity:

  99.81

• Solubility:

  DMSO : 12 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  NC1=NC (N2CCC (C) (N) CC2) =CN=C1C3=CC=CC (Cl) =C3Cl

• Molecular Formula:

  C16H19Cl2N5

• Molecular Weight:

  352.26

• Precautions:

  H315, H319, H320

• References & Citations:

  [2]Sun X, et al. Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia. 2018 May;32 (5) :1246-1249.|[1]Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016 Jul 7;535 (7610) :148-52.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  ACS Nano. 2023 Aug 22;17 (16) :16056-16068.|Acta Pharm Sin B. 2022 Jan;12 (1) :149-166.|Acta Pharm Sin B. 2022 Jul;12 (7) :3073-3084.|Acta Pharm Sin B. 2024 Jun;14 (6) :2598-2612.|Ann Transl Med. 2020 Dec;8 (23) :1570.|Biochem Biophys Res Commun. 2023 Oct 8:676:121-131.|Biochem Biophys Res Commun. 2024 May 21:709:149812.|Biochem Biophys Res Commun. 2025 Jun 14:776:152209.|bioRxiv. 2019 Sep.|bioRxiv. 2024 Feb 5.|bioRxiv. 2024 November 06.|bioRxiv. 2025 Aug 2:2025.07.31.667978.|bioRxiv. 2025 Oct 26.|Br J Cancer. 2023 Feb;128 (4) :678-690.|Brain Pathol. 2020 Mar;30 (2) :373-385.|Cancer Cell Int. 2021 Jul 3;21 (1) :337.|Cancer Res Commun. 2022 Sep;2 (9) :1061-1074.|Cancer Res. 2021 Jun 15;81 (12) :3215-3228.|Cancers (Basel) . 2022 May 12;14 (10) :2377.|Cell Rep. 2019 Aug 27;28 (9) :2331-2344.e8.|Cell Rep. 2019 Aug 27;28 (9) :2331-2344.e8.|Cell Syst. 2020 Nov 18;11 (5) :478-494.e9.|Commun Biol. 2020 Mar 17;3 (1) :128. |Eur J Med Chem. 2025 Jun 27:297:117918.|Exp Cell Res. 2022 Nov 15;420 (2) :113361.|Exp Mol Med. 2020 Jun;52 (6) :911-920.|Exp Ther Med. 2022 Apr;23 (4) :302.|FEBS Open Bio. 2020 Dec;10 (12) :2578-2587.|Front Immunol. 2021 Jan 21:11:610523.|Hematol Oncol. 2024 Jan;42 (1) :e3233.|Hepatology. 2018 Jul;68 (1) :333-348.|Hepatology. 2020 Jul;72 (1) :155-168. |Inflamm Res. 2023 Jul;72 (7) :1501-1512.|J Biol Chem. 2024 Jul 30:107616.|J Cell Biol. 2025 Oct 16;224 (12) .|J Exp Med. 2022 Apr 4;219 (4) :e20210739.|J Histochem Cytochem. 2025 Jan-Feb;73 (1-2) :63-79.|J Immunol Res. 2020 Jun 19;2020:4598476.|J Immunol. 2021 Sep 1;207 (5) :1419-1427.|J Magn Reson Imaging. 2025 Apr;61 (4) :1996-2008.|J Orthop Translat. 2022 Feb 17;32:112-120.|MedComm (2020) . 2022 Mar 4;3 (1) :e120.|Microvasc Res. 2022 Sep:143:104397.|Mol Cell. 2021 Oct 7;81 (19) :4076-4090.e8.|Mol Med. 2024 Apr 9;30 (1) :47.|Nano Today. 2025 Apr.|Nat Chem Biol. 2025 Aug;21 (8) :1226-1237.|Nat Commun. 2019 Apr 1;10 (1) :1473. |Nat Commun. 2023 Apr 6;14 (1) :1933.|Nat Commun. 2018 Oct 30;9 (1) :4507. |Nat Immunol. 2021 Nov;22 (11) :1391-1402.|Neural Regen Res. 2025 Mar 1;20 (3) :858-872.|Neuro Oncol. 2019 Nov 4;21 (11) :1423-1435. |Neuro Oncol. 2025 Mar 6:noaf057.|NPJ Precis Oncol. 2024 Jul 16;8 (1) :144.|Patent. US20190231805A1.|Patent. US20220380385A1.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Mar.|Sci Rep. 2023 Jun 20;13 (1) :10041.|Sci Transl Med. 2025 May 7;17 (797) :eads2694.|Signal Transduct Target Ther. 2022 Sep 12;7 (1) :317.|SSRN. 2020 May.|Theranostics. 2021 Jan 1;11 (2) :555-566.|Thromb Res. 2023 Aug:228:105-116.|Acta Pharm Sin B. 2022 Jan;12 (1) :149-166.|Cancer Discov. 2018 Oct;8 (10) :1237-1249. |Cancer Res Commun. 2023 Dec 27;3 (12) :2608-2622.|Cancer Res. 2020 Aug 15;80 (16) :3413-3423.|Inflammation. 2021 Aug;44 (4) :1529-1539.|J Control Release. 2025 May 25:384:113889.|Open Biol. 2017 May;7 (5) . pii: 170066.|Patent. US20200330595A1.

• CAS Number:

  1801747-42-1